Clinical trial
Precision Medicine Strategies for Advanced Esophageal Cancer Refractory to Immune Checkpoint Inhibitors
NCT07653451 is registered in ClinicalTrials.gov with Peking University Cancer Hospital & Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Precision Medicine Strategies for Advanced Esophageal Cancer Refractory to Immune Checkpoint Inhibitors
- Lead sponsor
- Peking University Cancer Hospital & Institute
- Phase
- Phase 2/3
- Overall status
- Not yet recruiting
- Start date
- July 1, 2026
- Completion date
- December 31, 2028
- Enrollment
- 90 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.